Sam Fazeli

Or could it simply be that the patients had, you know, biology just trumped things?

I don't know whatever that means, but you know.

And just to add, there is no known mechanism by which

the ADC is excluded from the tumor.

So you gave two possible mechanisms, the chemo and the antibody.

Is there ever, have you seen any change in the stromal structure or the structure of the tumor, even in mice, et cetera?

I don't know.

That would suggest that could be a mechanism of resistance.

Okay so I suspect you're going to tell me that it's my problem to go and figure out how DB11 and DB05 impact DB09 and DB03 use.

It's unfair because I didn't put it on my list of questions when I sent it to you.

Do you have on top of your mind the percentage of patients who present metastatic disease having been through surgery and adjuvant therapy?

Do you have it?

It's probably in the epi data that you've been providing.

So I'll go back.

It's on your website again, right?

Right.

A couple of questions on HR positive.

I mean, you didn't really this wasn't a meeting about the oral certs, but I think this question was posed during the analyst meeting, too.

But but if you wanted to just touch on it here quickly, what does obviously you have some some potential competitors in the space of oral certs, Rosh.

et cetera.